In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Multimodality Treatment of Arteriovenous Malformations of Basal Ganglia and Thalamus: Factors that Affect Outcome

    Final Number:
    1073

    Authors:
    Jeremiah N. Johnson MD; Nitin Mukerji MBBS, MD, FRCS, MSc; Paritosh Pandey MD; Mario Teo MBChB(Hons) BMedSci(Hons) FRCS(SN); Gary K. Steinberg MD, PhD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2015 Annual Meeting

    Introduction: We report the results of multimodality management of basal ganglia and thalamic AVMs at our institution and investigate the factors that influence outcomes.

    Methods: A prospectively maintained database of all vascular patients treated at our center was reviewed and appropriate patients identified. Demographics, radiological data, treatment methods as well as clinical follow-up and outcomes were collected and analyzed. Both univariate and multivariate analyses were conducted to explore the influence of various factors on outcome.

    Results: Analyses of 112 patients treated over 33 years are presented. In this cohort, 99% of patients were symptomatic and 75% presented with hemorrhage. Good outcomes (mRS < 3) were observed in 67% of all patients and in 42% of patients with grade 4 or 5 AVMs at a mean follow-up of 5.1 years (0.25-18). Annual risk of hemorrhage by the person-years method was significantly less after treatment (5.7% vs. 10.3%, P = .004). Repeat hemorrhage (OR = 15, P = <.001), higher grade (OR = 12, P = .001) and pre-treatment mRS (OR = 11, P = .001) were the strongest independent predictors of a poor outcome (mRS>2).

    Conclusions: Good outcomes are achievable with multimodality treatment in these complex patients. As recurrent hemorrhage is the strongest predictor of outcome and hemorrhage rates are significantly lessened by treatment, we recommend early treatment of symptomatic deep AVMs via carefully selected multimodality therapy strategies.

    Patient Care: By improving the understanding of deep AVMs natural history, promote discussion of treatment strategies and understanding of outcomes of patients undergoing multimodality treatment for symptomatic Basal Ganglia and Thalamic AVMs

    Learning Objectives: By the conclusion of this session, participants should understand the natural history of deep AVMs, be able to describe the role of multimodality management strategies and the discuss the factors that affect functional outcomes of symptomatic patients with Basal Ganglia and Thalamic AVMs.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy